Role of COX-2 specific inhibitors in oncogenesis

Journal of the College of Physicians and Surgeons Pakistan

Volumn 13, Issue 6, 2003, Pages 361-365

  Gumgumji, Abbas Ali ^a   Dawood, Talal ^a   Parvez, Tariq ^a  

^a KING FAHAD HOSPITAL   (Saudi Arabia)

Author keywords

Cancer; Cyclooxygenase 2(COX 2); Hepatocellular carcinoma; Oncogenesis; Prostaglandin(PG)

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EMODIN; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; APOPTOSIS; BILE DUCT CARCINOMA; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLORECTAL CANCER; ENZYME INHIBITION; ESOPHAGUS CANCER; GASTROINTESTINAL SYMPTOM; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PEPTIC ULCER; REVIEW; SQUAMOUS CELL CARCINOMA; THROMBOCYTE FUNCTION; XENOBIOTIC METABOLISM;

CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; LUNG NEOPLASMS;

EID: 0038042765     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Menter DG. Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin Investig Drugs 2002; 11: 1749-64.
2. Oshima M, Taketo MM. COX inhibitor, suppression of polyposis, and chemoprevention. Nippon Yakurigaku Zasshi 2002; 120: 276-84.
3. Cho H, Tai H. Inhibition of NAD (+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 461-5.
4. Kawai N, Tsujii M, Tsuji S. Cyclooxygenases and colon cancer. Prostaglandins Other Lipid Mediat 2002; 68-69: 187-96.
5. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94 : 252-66.
6. Nakamura H. Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors. Nippon Yakurigaku Zasshi 2001; 118: 219-30.
7. Ballinger A, Smith G. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention. Expert Opin Pharmacother 2001; 2: 31-40.
8. Elder DJ, Halton DE, Playle LC, Paraskeva C. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002; 99: 323-7.
9. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 2000; 19: 5517-24.
10. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 2002; 21: 155-64.
11. Blanke CD. Celecoxib with chemotherapy in colorectal cancer. Oncology (Huntingt) 2002; 16 (4 suppl. 3): 17-21.
12. Rex DK. Screening for colon cancer and evaluation of chemoprevention with coxibs. J Pain Symptom Manage 2002; 23 (4 suppl.): S41-50.
13. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8: 289-93.
14. Eschwege P, de Ledinghen V, Camilli T, Kulkarni S, Dalbagni G, Droupy S, et al. Arachidonic acid and prostaglandins, inflammation and oncology. Presse Med 2001; 30 : 508-10.
15. Kundu N, Smyth MJ, Samsel L, Fulton AM. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat 2002; 76: 57-64.
16. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002; 62: 2029-33.
17. Pan MR, Chuang LY, Hung WC. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 2001; 508: 365-8.
18. Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, Girod DA, et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001: 127: 1253-9.
19. Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001; 276: 3208-15.
20. Dermond O, Ruegg C. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. Drug Resist Update 2001; 4: 314-21.
21. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3: 53-61.
22. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2: 544-51.
23. Xu XC. COX-2 inhibitors in cancer treatment and prevention: a recent development. Anticancer Drugs 2002; 13: 127-37.
24. Giercksky KE. COX-2 inhibition and prevention of cancer. Best Pract Res Clin Gastroenterol 2001; 15: 821-33.
25. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Celecoxib strongly suppressed the proliferation of COX-2. FEBS Lett 2002; 531: 278-84.
26. Nagatsuka I, Yamada N, Shimizu S, Ohira M, Nishino H, Seki S, et al. Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int J Cancer 2002; 100: 515-9.
27. Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem Toxicol 2002; 40:1091-7.
28. Vaisman N, Arber N. The role of nutrition and chemoprevention in colorectal cancer: from observations to expectations. Best Pract Res Clin Gastroenterol 2002; 16:201-17.
29. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-72.
30. Hruban RH, Wilentz RE, Goggins M, Offerhaus GJ, Yeo CJ, Kern SE. Pathology of incipient pancreatic cancer. Ann Oncol 1999; 10(suppl 4):9-11.
31. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25:579-86.
32. Goggins M, Hruban RH, Kern SE. BRCA 2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 2000; 156: 1767-71.
33. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156:1821-5.
34. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000; 37: 431-502.
35. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Mondo M, Noura S, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999; 5: 2018-24.
36. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, et al. Cyclo-oxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000; 21: 139-46.
37. Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 2002; 118: 194-201.
38. Kohno H, Nagasue N, Rahman MA. COX-2 - a target for preventing hepatic carcinoma? Expert Opin Ther Targets 2002; 6: 483-90.
39. Sirica AE, Lai GH, Endo K, Zhang Z, Yoon BI. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 2002; 22 : 303-13.
40. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999;10(suppl 4): S308-S11.
41. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-7.
42. Shirabe K, Shimada M, Harimoto N, Sugimachi K, Yamashita Y, Tsujita E, et al. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery 2002; 131(suppl): S159-S64.
43. Bathe OF, Pacheco JT, Ossi PB, Hamilton KL, Franceschi D, Sleeman D, et al. Management of hilar bile duct carcinoma. Hepatogastroenterology 2001; 48: 1289-94.
44. Su WC, Shiesh SC, Liu HS, Chen CY, Chow NH, Lin XZ. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci 2001; 46: 1387-92.
45. Yu D, Hung MC. Overexpression of ERBB2 in cancer and ErbB2-targeting strategies. Oncogene 2000; 19: 6115-21.
46. Buskens CJ, van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122: 1800-7.
47. Gridelli C, Maione P, Airoma G, Rossi A. Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr Med Chem 2002; 9: 1851-8.
48. Liu LT, Chang HC, Chiang LC, Hung WC. Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells. Oncogene 2002; 21: 8347-50.
49. Qadri SS, Wang JH, Redmond KC, O'Donnell AF, Aherne T, Redmond HP. The role of COX-2 inhibitors in lung cancer. Ann Thorac Surg 2002; 74: 1648-52.
50. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53: 232-40.
51. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58: 127-31.
52. Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001; 21(2B): 1291-4.
53. Singh-Ranger G, Mokbel K. Current concepts in cyclooxygenase inhibition in breast cancer. J Clin Pharm Ther 2002; 27: 321-7.
54. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-60.
55. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002; 24: 792-9.
56. Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res 2002; 22: 2089-96.
57. Fischer SM. Is cyclooxygenase-2 important in skin carcinogenesis? J Environ Pathol Toxicol Oncol 2002; 21: 183-91.
58. Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002; 160: 893-903.
59. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001; 61: 303-8.
60. Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000; 157: 29-35.
61. Howe LR, Dannenberg AJ. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 2002; 29 (3 suppl 11): 111-9.
62. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002; 62: 3956-61.
63. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001; 11: 290-9.
64. Ricciardiello L, Roda E, Bazzoli F. Chemoprevention in colorectal neoplasias: what is practical and feasible? Dig Dis 2002; 20: 70-2.
65. Blanke CD, Benson AB, Dragovich T., A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC) (abstract 505). Program and abstracts of the American Society of Clinical Oncology 38th Annual Meeting; May 18-21, 2002; Orlando, Florida: American Society of Oncology 2002.